- Title
- Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
- Creator
- Hofman, Michael S.; Lawrentschuk, Nathan; Wong, Lih-Ming; Taubman, Kim; Ting Lee, Sze; Hsiao, Edward; Roach, Paul; Nottage, Michelle; Kirkwood, Ian; Hayne, Dickon; Link, Emma; Marusic, Petra; Francis, Roslyn J.; Matera, A; Herschtal, A; Iravani, A; Hicks, RJ; Williams, S; Murphy, DG; Tang, Colin; Vela, Ian; Thomas, Paul; Rutherford, Natalie; Martin, Jarad M.; Frydenberg, Mark; Shakher, Ramdave
- Relation
- The Lancet Vol. 395, Issue 10231, p. 1208-1216
- Publisher Link
- http://dx.doi.org/10.1016/S0140-6736(20)30314-7
- Publisher
- The Lancet Publishing Group
- Resource Type
- journal article
- Date
- 2020
- Description
- Background: Conventional imaging using CT and bone scan has insufficient sensitivity when staging men with high-risk localised prostate cancer. We aimed to investigate whether novel imaging using prostate-specific membrane antigen (PSMA) PET-CT might improve accuracy and affect management. Methods: In this multicentre, two-arm, randomised study, we recruited men with biopsy-proven prostate cancer and high-risk features at ten hospitals in Australia. Patients were randomly assigned to conventional imaging with CT and bone scanning or gallium-68 PSMA-11 PET-CT. First-line imaging was done within 21 days following randomisation. Patients crossed over unless three or more distant metastases were identified. The primary outcome was accuracy of first-line imaging for identifying either pelvic nodal or distant-metastatic disease defined by the receiver-operating curve using a predefined reference-standard including histopathology, imaging, and biochemistry at 6-month follow-up. This trial is registered with the Australian New Zealand Clinical Trials Registry, ANZCTR12617000005358. Findings: From March 22, 2017 to Nov 02, 2018, 339 men were assessed for eligibility and 302 men were randomly assigned. 152 (50%) men were randomly assigned to conventional imaging and 150 (50%) to PSMA PET-CT. Of 295 (98%) men with follow-up, 87 (30%) had pelvic nodal or distant metastatic disease. PSMA PET-CT had a 27% (95% CI 23–31) greater accuracy than that of conventional imaging (92% [88–95] vs 65% [60–69]; p<0·0001). We found a lower sensitivity (38% [24–52] vs 85% [74–96]) and specificity (91% [85–97] vs 98% [95–100]) for conventional imaging compared with PSMA PET-CT. Subgroup analyses also showed the superiority of PSMA PET-CT (area under the curve of the receiver operating characteristic curve 91% vs 59% [32% absolute difference; 28–35] for patients with pelvic nodal metastases, and 95% vs 74% [22% absolute difference; 18–26] for patients with distant metastases). First-line conventional imaging conferred management change less frequently (23 [15%] men [10–22] vs 41 [28%] men [21–36]; p=0·008) and had more equivocal findings (23% [17–31] vs 7% [4–13]) than PSMA PET-CT did. Radiation exposure was 10·9 mSv (95% CI 9·8–12·0) higher for conventional imaging than for PSMA PET-CT (19·2 mSv vs 8·4 mSv; p<0·001). We found high reporter agreement for PSMA PET-CT (κ=0·87 for nodal and κ=0·88 for distant metastases). In patients who underwent second-line image, management change occurred in seven (5%) of 136 patients following conventional imaging, and in 39 (27%) of 146 following PSMA PET-CT. Interpretation: PSMA PET-CT is a suitable replacement for conventional imaging, providing superior accuracy, to the combined findings of CT and bone scanning.
- Subject
- prostate; cancer; surgery; bone scan; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1443306
- Identifier
- uon:41947
- Identifier
- ISSN:0140-6736
- Language
- eng
- Reviewed
- Hits: 13019
- Visitors: 13002
- Downloads: 0
Collections
Goal 3: Good Health and Well-Being